Mefloquine targets NLRP3 to reduce lipopolysaccharide-induced systemic inflammation and neural injury.

Jiang, Si-Yuan; Tian, Tian; Li, Wen-Jie; Liu, Ting; Wang, Cong; Hu, Gang; Du, Ren-Hong; Liu, Yang; Lu, Ming

Jiang, Si-Yuan; Tian, Tian; Li, Wen-Jie; Liu, Ting; Wang, Cong; Hu, Gang; Du, Ren-Hong; Liu, Yang; Lu, Ming.

Afiliação

Jiang SY; Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China.
Tian T; Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China.
Li WJ; Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China.
Liu T; Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China.
Wang C; Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China.
Hu G; Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China.
Du RH; Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China.
Liu Y; Department of Pharmacology, Nanjing University of Chinese Medicine, Nanjing, China.
Lu M; Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China.

EMBO Rep ; 24(10): e57101, 2023 Oct 09.

Article em En | MEDLINE | ID: mdl-37621232

Palavras-chave

NLRP3; Parkinson's disease; inflammation; inhibitor; mefloquine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: EMBO Rep Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google